Navigation Links
Cocaine: How addiction develops
Date:8/21/2008

Permanent drug seeking and relapse after renewed drug administration are typical behavioral patterns of addiction. Molecular changes at the connection points in the brain's reward center are directly responsible for this. This finding was published by a research team from the Institute of Mental Health (ZI) in Mannheim, the German Cancer Research Center (DKFZ) in Heidelberg and the University of Geneva, Switzerland, in the latest issue of Neuron. The results provide researchers with new approaches in the medical treatment of drug addiction.

Addiction leaves detectable traces in the brain: In particular regions of the central nervous system, which produce the messenger substance dopamine, the drug cocaine causes molecular restructuring processes at the synapses, the points of connection between two neurons. As a reaction to the drug, protein subunits are exchanged in specific receptor complexes. As a result, the modified synapse becomes able to transmit nervous signals with enhanced strength a phenomenon that has been termed 'drug-induced synaptic plasticity'. Researchers have suspected for many years that drug-induced synaptic plasticity plays a crucial role in addiction development. However, this hypothesis has not yet been proven experimentally.

Using genetic engineering, researchers headed by Professor Dr. Gnther Schtz at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now been able to selectively switch off those protein components in dopamine-producing neurons that are integrated into the receptor complexes under the influence of cocaine. Jointly with the team of Professor Dr. Rainer Spanagel at the Central Institute of Mental Health (Zentralinstitut fr Seelische Gesundheit, ZI) in Mannheim and the research group of Professor Dr. Christian Lscher at Geneva University, the Heidelberg researchers studied the changes in physiology and behavior of the genetically modified animals.

The scientists performed standardized tests to measure addictive behavior in the animals. At first sight, both the genetically modified and the control animals displayed the usual behavior under the influence of cocaine. Forced to increase their agility, the lab animals covered significantly greater running distances and preferentially frequented those places where they had been conditioned to be regularly administered the drug.

If normal mice do not find drugs at the familiar places over a longer period of time, their addictive behavior and preference for the cocaine-associated places subside. However, this is not true for animals whose receptor subunit GluR1 has been switched off: These mice invariably frequent the places where they expect to find the drug, i.e., their addictive behavior persists.

Mice whose NR1 protein has been switched off have surprised scientists with a different conspicuous behavior. If control animals withdrawn from cocaine are readministered the drug after some time, addictive behavior and drug seeking are reactivated. In contrast, NR1 deficient animals proved to be resistant to relapsing into the addiction.

"It is fascinating to observe how individual proteins can determine addictive behavioral patterns," says Gnther Schtz, and his colleague Rainer Spanagel adds: "In addition, our results open up whole new prospects for treating addiction. Thus, blocking the NR1 receptor might protect from relapsing into addiction. Selective activation of GluR1 would even contribute to 'extinguishing' the addiction."


'/>"/>

Contact: Dr. Sibylle Kohlstdt
s.kohlstaedt@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Related biology news :

1. Nicotinic receptors may be important targets for treatment of multiple addictions
2. New genetic research into nicotine addiction shows promise for personalized treatment
3. Can plant-based ethanol save us from our fossil fuel addiction?
4. Cognitive, genetic clues identified in imaging study of alcohol addiction
5. Hungry mothers risk addiction in their adult children
6. Corals addiction to junk food
7. Erasing drug-associated memories may stop drug addiction relapses
8. Large-scale investment catapults CAMHs mental illness and addiction research forward
9. How schizophrenia develops: Major clues discovered
10. MIT develops tractor beam for cells, more
11. Team of scientists develops non-invasive method to track nerve-cell development in live human brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... DENVER , Jan. 23, 2017  The latest ... biometric smartphone prices have dropped dramatically. The quarterly average ... Q1 2013 to $276 in Q4 2016.  There are ... average price of $116, up from just 28 a ... According to Maxine Most , Acuity ...
(Date:1/18/2017)... Jan. 18, 2017  In vitro diagnostic (IVD) companies ... and acquisitions (M&A), and Kalorama Information expects that trend ... have been shifting. Generally, uncertainty in reimbursement and healthcare ... U.S. has changed the acquisitions landscape. Instead of looking ... companies buying partners outside of their home country and ...
(Date:1/12/2017)... NEW YORK , Jan. 12, 2017  New research ... around the office of the future.  1,000 participants were simply ... last three months which we may consider standard issue.  Insights ... office of 2017 were also gathered from futurists and industry ... and Dr. James Canton .  Some ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... ... February 17, 2017 , ... Academy of Model Aeronautics (AMA), ... maker of unmanned aircraft systems (UAS), are launching a joint program to promote ... and support educational outreach efforts. , AMA and DJI will collaborate on other ...
(Date:2/16/2017)... GREENWICH, Conn. , Feb. 16, 2017 ... on venture growth investments in biotechnology and medical ... Richardson , M.D. to Managing Director. ... He is a board observer at InfaCare Pharmaceutical ... investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence Pharmaceuticals ...
(Date:2/16/2017)... 16, 2017   Biostage, Inc. (Nasdaq: ... company developing bioengineered organ implants to treat cancers and ... announced today the closing on February 15, 2017 of ... common stock and warrants to purchase 20,000,000 shares of ... The offering was priced at $0.40 per share of ...
(Date:2/16/2017)... ... February 16, 2017 , ... AxioMed announced today the ... Harvard trained surgeon, completed the procedure on Monday, Jan. 30 at Andrews Memorial ... physician suffering from degenerative disc disease with radiculomyelopathy, as a result of degenerative ...
Breaking Biology Technology: